GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chengdu Easton Biopharmaceuticals Co Ltd (SHSE:688513) » Definitions » ROIC %

Chengdu Easton Biopharmaceuticals Co (SHSE:688513) ROIC % : 16.78% (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Chengdu Easton Biopharmaceuticals Co ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Chengdu Easton Biopharmaceuticals Co's annualized return on invested capital (ROIC %) for the quarter that ended in Mar. 2024 was 16.78%.

As of today (2024-05-26), Chengdu Easton Biopharmaceuticals Co's WACC % is 5.52%. Chengdu Easton Biopharmaceuticals Co's ROIC % is 13.31% (calculated using TTM income statement data). Chengdu Easton Biopharmaceuticals Co generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Chengdu Easton Biopharmaceuticals Co ROIC % Historical Data

The historical data trend for Chengdu Easton Biopharmaceuticals Co's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chengdu Easton Biopharmaceuticals Co ROIC % Chart

Chengdu Easton Biopharmaceuticals Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROIC %
Get a 7-Day Free Trial 31.44 31.57 21.54 17.15 12.41

Chengdu Easton Biopharmaceuticals Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.07 16.22 14.04 6.17 16.78

Competitive Comparison of Chengdu Easton Biopharmaceuticals Co's ROIC %

For the Biotechnology subindustry, Chengdu Easton Biopharmaceuticals Co's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chengdu Easton Biopharmaceuticals Co's ROIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chengdu Easton Biopharmaceuticals Co's ROIC % distribution charts can be found below:

* The bar in red indicates where Chengdu Easton Biopharmaceuticals Co's ROIC % falls into.



Chengdu Easton Biopharmaceuticals Co ROIC % Calculation

Chengdu Easton Biopharmaceuticals Co's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROIC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=207.213 * ( 1 - 6.23% )/( (1449.091 + 1682.261)/ 2 )
=194.3036301/1565.676
=12.41 %

where

Invested Capital(A: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3017.54 - 388.714 - ( 1347.33 - max(0, 529.387 - 1709.122+1347.33))
=1449.091

Invested Capital(A: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3346.754 - 442.716 - ( 1523.013 - max(0, 661.094 - 1882.871+1523.013))
=1682.261

Chengdu Easton Biopharmaceuticals Co's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Mar. 2024 is calculated as:

ROIC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=301.908 * ( 1 - 6.34% )/( (1682.261 + 1687.177)/ 2 )
=282.7670328/1684.719
=16.78 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3346.754 - 442.716 - ( 1523.013 - max(0, 661.094 - 1882.871+1523.013))
=1682.261

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3374.371 - 450.179 - ( 1487.641 - max(0, 666.672 - 1903.687+1487.641))
=1687.177

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chengdu Easton Biopharmaceuticals Co  (SHSE:688513) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Chengdu Easton Biopharmaceuticals Co's WACC % is 5.52%. Chengdu Easton Biopharmaceuticals Co's ROIC % is 13.31% (calculated using TTM income statement data). Chengdu Easton Biopharmaceuticals Co generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases. Chengdu Easton Biopharmaceuticals Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Chengdu Easton Biopharmaceuticals Co ROIC % Related Terms

Thank you for viewing the detailed overview of Chengdu Easton Biopharmaceuticals Co's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Chengdu Easton Biopharmaceuticals Co (SHSE:688513) Business Description

Traded in Other Exchanges
N/A
Address
No. 8, Xiyuan Avenue, Chengdu High-tech Zone, Sichuan Province, Chengdu, CHN, 611731
Chengdu Easton Biopharmaceuticals Co Ltd is engaged in research and development, production and sales of chemical raw materials and chemical pharmaceutical preparations. The company's products range from Active Pharmaceutical Ingredient to finish dosage forms like capsules, tablets and injections, enabling us to take R&D discovery to industrial level, solving problems during the course of R&D, production and distribution. Its products are categorized under Active Pharmaceutical Ingredients and Fixed Dose Formulation.

Chengdu Easton Biopharmaceuticals Co (SHSE:688513) Headlines

No Headlines